|
Variable
|
Score
|
Neo-adjuvant Chemotherapy
|
No Neo-adjuvant Chemotherapy
|
P value*
|
|---|
|
Age
|
>Median
|
9
|
15
|
0.073
|
|
< Median
|
27
|
16
|
|
Histology
|
Adenocarcinoma
|
31
|
24
|
0.180
|
|
Squamous
|
5
|
7
|
|
Stage
|
I
|
11
|
3
|
0.109
|
|
II
|
10
|
12
|
|
III
|
15
|
16
|
|
Site
|
Oesophagus
|
30
|
25
|
0.755
|
|
(includes Siewert Type I and II junctional)
| | |
| |
6
|
6
|
|
Gastric
| | |
|
(includes Siewert Type III junctional)
| | |
|
Circumferential Resection Margins
|
Positive
|
6
|
11
|
0.378
|
|
Negative
|
30
|
20
|
- There was no significant difference in clinic-pathological characteristics between patients who did and did not receive neo-adjuvant chemotherapy prior to surgery. SPHK1 immunohistochemistry was performed on this cohort as described. *χ2 test. Two-sided p value
